stockrow
Wednesday 4 November 2026
Export CAPR’s income statement to Excel — free account
Capricor Therapeutics, Inc.
CAPR Healthcare Biotechnology
Capricor Therapeutics, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $22.3 million, down 11.5% from fiscal 2023.
- Revenue
- −7.92%
- EPS
- −22.8%
- Free cash flow
- −72.9%
Quarter to June 2026, against a year earlier
8.89
0.65
+7.89%
Follow CAPR
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (73.70%) | (56.40%) | (46.56%) | (107.79%) |
+8 more TTM periods Free account |
|
| (51.53%) | (47.74%) | (39.91%) | (74.74%) | ||
ROIC |
(1,019.73%) | (80,860.30%) | 0.00% | 0.00% | |
Return on Tangible Assets |
(52.71%) | (41.23%) | (34.39%) | (97.76%) | |
Average Days of Receivables |
— | — | 0.00 | 0.00 | |
Free Cash Flow per Share |
2.26 | 2.55 | 3.85 | 0.56 | |
Free Cash Flow |
130.91 | 146.63 | 179.06 | 25.42 | |
Capital Expenditures |
234.91 | 239.27 | 248.87 | 86.46 | |
| Other line items | |||||
Cash ROIC |
27.04% | 26.31% | 28.70% | 13.93% | |
Accounts Receivable Turnover |
— | — | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.80 | 0.81 | 0.66 | 0.74 | |
Depreciation/Fixed assets |
0.02 | 0.06 | 0.10 | 0.16 | |
Capex/Depreciation |
278.95 | 144.18 | 131.75 | 49.06 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.80) | (1.61) | (1.50) | (1.34) | |
Capex per Share |
4.06 | 4.17 | 5.35 | 1.89 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates